PCI1

Partner Content

PCI Pharma Services completes acquisition of Ajinomoto Althea

Part of $1 billion investment strategy, PCI Pharma Services completes acquisition of Ajinomoto Althea, enhancing US drug product manufacturing for aseptic filling of prefilled syringes & cartridges.

Partner Content

Five considerations when scaling up mAbs in partnership with a CDMO

Partner Content

Overcoming regulatory challenges in sterile manufacturing

Partner Content

The development of novel drugs: the role of lyophilization

News

Emergent to sell US sterile manufacturing facility to Bora

Sign up to the newsletter: In Brief

I would also like to subscribe to:

Pharma Technology Focus : Focus (monthly)

Thematic Take (monthly)

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close

Sections

Sections

Sections

Sections

Sections

Sections

PCI Pharma Services completes acquisition of Ajinomoto Althea

Five considerations when scaling up mAbs in partnership with a CDMO

Overcoming regulatory challenges in sterile manufacturing

The development of novel drugs: the role of lyophilization

Emergent to sell US sterile manufacturing facility to Bora

Digital health and digital therapeutics (DTx) services and providers for the pharmaceutical industry

Leading Artificial Intelligence (AI) Companies in Pharma

Sign up for our daily news round-up!

Sign up to the newsletter: In Brief